

## press release

### **Novo Nordisk UK confident of supply amid Coronavirus outbreak**

**Gatwick, April 20 2020** – As the biggest insulin supplier in the UK and with 95 years of innovation in diabetes care, Novo Nordisk is dedicated to ensuring medicine supplies are unaffected during the current Coronavirus outbreak. Our patients, the NHS and our people are at the heart of everything we do.

We understand the pressure on the NHS at this time, and to minimise the possibility of infection moving from one service to another, we have invested in technology to allow our teams to work from home virtually. This allows us to ensure continuity of services to our patients and to the NHS, whilst also supporting our people and their families by reducing the risk of infection through interactions at work. We are confident that we have taken all possible steps to ensure we can continue to supply the patients we serve.

We have robust plans in place to ensure a strong continuation of supply to bring our essential, lifesaving, medicines into the UK. As it stands, Novo Nordisk is in a good position, with high stock levels in the UK, to continue to ensure patients get access to the medicines and treatments they need. We encourage Health Care Professionals to prescribe at a normal rate to allow us to plan our stock levels and to distribute our medicines and treatments in our normal way.

We are speaking with the Government, Department of Health and Social Care, doctors, patient group representatives and our industry trade association, the Association of the British Pharmaceutical Industry (ABPI) to ensure a united approach to supporting the country with containing this outbreak.

Pinder Sahota, Corporate Vice President of Novo Nordisk UK said, "During this unprecedented time, Novo Nordisk is doing all we can to respond to the Coronavirus outbreak. Our first commitment is to ensure that our patients continue to get access to the lifesaving medicine that they need. We have taken all necessary steps to ensure continuity of supply to UK patients."

-END-

## **About Novo Nordisk**

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 42,700 people in 80 countries and markets its products in around 170 countries. For more information, [novonordisk.co.uk](http://novonordisk.co.uk)

*Juliet Scott*

+44 (0)7557490116

[zjls@novonordisk.com](mailto:zjls@novonordisk.com)

*Abby Purdy*

+44 (0)787 2506 607

[Abby.Purdy@Syneoshealth.com](mailto:Abby.Purdy@Syneoshealth.com)

Novo Nordisk Ltd  
Corporate Communications

3 City Place Beehive Ring Road  
Gatwick West Sussex RH6 0PA

Telephone:  
+44 1293 613555

Internet:  
[www.novonordisk.co.uk](http://www.novonordisk.co.uk)

Novo Nordisk Ltd  
Corporate Communications

3 City Place Beehive Ring Road  
Gatwick West Sussex RH6 0PA

Telephone:  
+44 1293 613555

Internet:  
[www.novonordisk.co.uk](http://www.novonordisk.co.uk)

Job ID: UK20DI00114  
Date of Prep – April 2020